Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia.

Leukemia · 2020 · PMC7450257 · PMID 32855439

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Trends toward lack of anti-SARS-CoV-2 IgG development for those currently receiving CLL-directed therapy or BTKi did not reach statistical significance in this small cohort.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.